The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

Living with chronic small lymphocytic lymphoma for the past 15 years has taught me some very valuable lessons, from dieting to managing anxiety. The FDA granted a fast track designation to BGB-16673, ...

RT is a change in disease histopathology from CLL or SLL to aggressive lymphoma, and it carries a poor prognosis, so the finding that its incidence was lower in the novel agent era—defined as ...

Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.

Small lymphocytic lymphoma (SLL), the tissue equivalent of chronic lymphocytic leukemia (CLL), typically presents with lymphadenopathy, organomegaly, and the presence of infiltrating monoclonal B ...

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL. Among patients with previously treated ...

We may be able to update survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma based on treatment-free interval length. Researchers from the Mayo Clinic ...

or small lymphocytic lymphoma, or SLL, previously treated with a covalent BTK inhibitor. The study met its primary endpoint of progression-free survival at primarily analysis, showing that ...

Quality improvement research projects selected for funding to enhance care and improve outcomes in common blood cancers. CLL/SLL is the most-commonly diagnosed form of leukemia in the United ...

Presentations Highlight Sustained Progression-Free Survival and Deepening Durable ... naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with no new safety signals observed.